Showing results (51-60 of 212) with videos related to
Sort By:
Pageof 22
Biophysical Journal|February 14, 2006
Measuring the elasticity of clathrin-coated vesicles via atomic force microscopyAlbert J Jin, Kondury Prasad, Paul D Smith, et al.Radiation Research|March 10, 2009
Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parametersNicole Y Morgan, Gabriela Kramer-Marek, Paul D Smith, et al.British Journal of Neurosurgery|June 18, 2009
Outcome from surgery for vestibular schwannomas in childrenStephen P MacNally, Scott A Rutherford, Andrew T King, et al.Journal of Neurosurgery|May 13, 2023
Does tumoral cavernous carotid stenosis predict an increased risk of future stroke in skull base meningiomas?Joshua I Macarthur, Frazer O'Brien, Cathal John Hannan, et al.Neuro-Oncology Advances|July 4, 2024
Evidence for inflammation in normal-appearing brain regions in patients with growing sporadic vestibular schwannoma: A PET studyBandar Alfaifi, Rainer Hinz, Alan Jackson, et al.Methods (San Diego, Calif.)|December 29, 2012
Unraveling protein-protein interactions in clathrin assemblies via atomic force spectroscopyAlbert J Jin, Eileen M Lafer, Jennifer Q Peng, et al.Chemical Reviews|July 22, 2020
Challenges and Opportunities in Cancer Drug ResistanceRichard A Ward, Stephen Fawell, Nicolas Floc'h, et al.Biochemical Society Transactions|January 21, 2012
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodellingAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.NAR Cancer|October 21, 2022
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistancePrasanna Channathodiyil, Kieron May, Anne Segonds-Pichon, et al.The Biochemical Journal|September 6, 2022
Combinatorial approaches for mitigating resistance to KRAS-targeted therapiesHannah R Warren, Sarah J Ross, Paul D Smith, et al.Pageof 22